Cargando…

Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks

Background: Hereditary angioedema (HAE) is a rare C1-inhibitor (C1-INH) deficiency disease involving recurrent painful episodes of severe swelling that should be promptly treated. Aims: To determine cost and utility estimates for on-demand treatment of HAE attacks in order to better clarify and cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tyson, Christopher, Relan, Anurag, Adams, Phillippe, Haynes, Angela, Magar, Raf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Poster #21
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764406/ http://dx.doi.org/10.1080/21556660.2019.1658300

Ejemplares similares

Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks
por: Bernstein, Jonathan A., et al.
Publicado: (2020)

The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews
por: Jean-Baptiste, Milenka, et al.
Publicado: (2022)

Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability
por: Diaz-Menindez, Maximiliano, et al.
Publicado: (2023)

Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial
por: Javaud, Nicolas, et al.
Publicado: (2016)

Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies
por: Wahn, V., et al.
Publicado: (2012)

Hereditary angioedema (HAE) in Belgium: results from a national survey
por: Van der Poorten, MM, et al.
Publicado: (2023)

Fast 3: a phase III randomized double-blind, placebo-controlled multicenter study of Icatibant for subcutaneous injection in patients with acute Attacks of Hereditary Angioedema (HAE)
por: Ritchie, B
Publicado: (2010)

Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
por: Guo, Yinshi, et al.
Publicado: (2022)

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019)

The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology
por: Bygum, Anette, et al.
Publicado: (2012)

A patient with hereditary angioedema (HAE) with normal C1-INH and SLE with pregnancy
por: Taha, Omar S., et al.
Publicado: (2022)

Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children
por: Reshef, Avner, et al.
Publicado: (2019)

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
por: Petkova, Elena, et al.
Publicado: (2022)

Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk
por: Reshef, A, et al.
Publicado: (2015)

85 Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks
por: Reshef, Avner, et al.
Publicado: (2012)

Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry()
por: Valerieva, Anna, et al.
Publicado: (2021)

Screening for hereditary angioedema (HAE) at 13 emergency centers in Osaka, Japan: A prospective observational study
por: Hirose, Tomoya, et al.
Publicado: (2017)

Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency (C1-INH-HAE)
por: Parsopoulou, Faidra, et al.
Publicado: (2022)

Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema
por: Steiner, Urs C., et al.
Publicado: (2018)

Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study()
por: Grumach, Anete S., et al.
Publicado: (2022)

Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series
por: Andarawewa, S., et al.
Publicado: (2022)

549 Management of Twenty-Five Pediatric Patients with Hereditary Angioedema (Hae) Undergoing Home Treatment—A Clinical Surveillance Program
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2012)

Treatment of hereditary angioedema with recombinant human C1 Inhibitor in a real-life setting: the experience of the HAE Centre in Milan
por: Zanichelli, Andrea, et al.
Publicado: (2015)

Real-world experience of hereditary angioedema (HAE) in Mexico: A mixed-methods approach to describe epidemiology, diagnosis, and treatment patterns
por: Nieto, Sandra, et al.
Publicado: (2023)

Hereditary Angioedema Attack in Utero and Treatment of the Mother and Fetus
por: Grivcheva-Panovska, Vesna, et al.
Publicado: (2020)

84 Immuno-Safety of Recombinant Human C1 Inhibitor in Patients With Hereditary Angioedema: An Integrated Analysis
por: Hack, Erik, et al.
Publicado: (2012)

A novel therapeutic concept for the treatment of acute angioedema attacks in hereditary angioedema patients: multiple successful treatments even in severe swelling attacks with the bradykinin-B2 receptor antagonist Icatibant
por: Bas, M, et al.
Publicado: (2006)

Management of acute attacks of hereditary angioedema: role of ecallantide
por: Duffey, Hannah, et al.
Publicado: (2015)

Laryngeal edema is common in HAE and demands preventive measures
por: Rosario, Cristine Secco, et al.
Publicado: (2015)

83 Hereditary Angioedema and Normal C1-Inhibitor (HAE TYPE III): A Novel Mutation in the Coagulation Factor 12 Gene
por: Bork, Konrad, et al.
Publicado: (2012)

Psychometric study of the SF-36v2 in hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE)
por: Palao-Ocharan, Paola, et al.
Publicado: (2022)

Patterns of on-demand medication use in patients with hereditary angioedema treated long-term with prophylactic subcutaneous C1-inhibitor
por: Levy, Donald S., et al.
Publicado: (2019)

Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency
por: Rubinstein, Eitan, et al.
Publicado: (2014)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

455 Characterization of the Factors Triggering an Edematous Attack in Hereditary Angioedema
por: Zotter, Zsuzsanna, et al.
Publicado: (2012)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

The Interplay of COVID-19 and Hereditary Angioedema: Preventing an Acute Attack
por: Park, Erin G, et al.
Publicado: (2022)

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
por: Lumry, William, et al.
Publicado: (2020)

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat
por: Cohn, Danny M., et al.
Publicado: (2023)

Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients
por: Federici, Carlo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7ol77cmupf988iqjmrk1b1k6uv